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After publication of this work [1], we were alerted to
an error in the reported cohort size used for the Radial
Arm Water Maze as referenced from [2]. The correct
cohort size reported in [2] is n=8-13 for each group of
mixed gender animals. In addition, it came to our atten-
tion that our analysis of a potential false-positive treat-
ment effect caused by gender differences, and therefore
bexarotene’s inability to rescue cognitive decline, may
appear to be contradicted by the statement that it “was
equally effective in both genders” of transgenic mice [2].
However, direct experimental data supporting this state-
ment is not presented. In addition, this statement does
not address any differences in the performance of each
gender, only that bexarotene appears effective in each
gender separately, and the statistical significance of this
reported effect remains unknown. Therefore, we main-
tain that the currently published cognitive preclinical
data, including our own, do not validate the potential of
bexarotene for Alzheimer’s therapy.”* Correspondence: troncoso@jhmi.edu; wong@jhmi.edu
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